Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 85-89 |
| Number of pages | 5 |
| Journal | Rhinology |
| Volume | 61 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1 Feb 2023 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Rhinology, Vol. 61, No. 1, 01.02.2023, p. 85-89.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - The EUFOREA pocket guide for chronic rhinosinusitis
AU - Hellings, P. W.
AU - Fokkens, W. J.
AU - Orlandi, R.
AU - Adriaensen, G. F.
AU - Alobid, I.
AU - Baroody, F. M.
AU - Bjermer, L.
AU - Senior, B. A.
AU - Cervin, A.
AU - Cohen, N. A.
AU - Constantinidis, J.
AU - de Corso, E.
AU - Desrosiers, M.
AU - Diamant, Z.
AU - Douglas, R. G.
AU - Gane, S.
AU - Gevaert, P.
AU - Han, J. K.
AU - Harvey, R. J.
AU - Hopkins, C.
AU - Kern, R. C.
AU - Landis, B. N.
AU - Lee, J. T.
AU - Lee, S. E.
AU - Leunig, A.
AU - Lund, V. J.
AU - Bernal-Sprekelsen, M.
AU - Mullol, J.
AU - Philpott, C.
AU - Prokopakis, E.
AU - Reitsma, S.
AU - Ryan, D.
AU - Salmi, S.
AU - Scadding, G.
AU - Schlosser, R. J.
AU - Steinsvik, A.
AU - Tomazic, P. V.
AU - van Staeyen, E.
AU - van Zele, T.
AU - Vanderveken, O.
AU - Viskens, A. S.
AU - Conti, D.
AU - Wagenmann, M.
N1 - Funding Information: Funding was provided via an unrestricted grant to EUFOREA by Sanofi Genzyme and Regeneron. Funding Information: Douglas: No conflict of interest to report. S. Gane: lecture fees and/or participation in at expert board meetings of GSK and Sanofi. Trustee for the AbScent and Rhinology and Laryngology Research Fund charities. P. Gevaert: PhG lecture fees and/or participationion at expert board meetings of 3NT, Ablynx, ALK, Argenx, AstraZeneca, Bekaert Textiles, Genentech, GSK, Hall Allergy, Medtronic, Novartis, Regeneron, Roche, Sanofi-Genzyme, Stallergenes-Greer, Teva, and Thermo Fisher. J.K. Han: No conflict of interest to report. R. J Harvey: consultant with Medtronic, Olympus, Novartis and NeilMed pharmaceuticals. He has also been on the speakers’ bureau for Glaxo-Smith-Kline, Meda Pharmaceutical, Seqiris and Astra-Zeneca. Research funding from Neilmed and Glaxo-Smith-Kline. C. Hopkins, R.C. Kern, B.N. Landis: No conflict of interest to report. J. T. Lee: consultant for medtronic, Stryker ent, sanofi, and Aerin medical. S.E. Lee: Clinical trial funding and advisory boards: AstraZeneca, Genentech, Glaxo Smith Kline, Genzyme, Optinose, Sanofi Regeneron. A. Leunig, V. Lund, M. Bernal-Sprekelsen: No conflict of interest to report. J. Mullol: AstraZeneca, Genentech, Inc., GlaxoSmith-Kline, Glenmark, Menarini, Mitsubishi-Tanabe, Merck Sharp & Dohme, Viatris (Mylan-MEDA), Novartis, Proctor & Gamble, Funding Information: W. Fokkens, R. Orlandi, G.F. Adriaensen: No conflict of interest to report. I. Alobid: Consultant for GSK, Novartis, Viatris, Sanofi, Roche, Olympus, and Salvat, F.M. Baroody, L. Bjermer, BA Senior, A. Cervin: No conflict of interest to report. N.A. Cohen: Has received research Funding from NIH-Veterans Affairs Administration; is Founding Partner of 4 Sinuses LLC. Is on the Scientific Advisory Board for Oyster Point Pharmaceuticals, Sanofi/Regeneron and GSK. Is a consultant for AstraZeneca and Bayer Health. Has a Patent: Therapy and Diagnostics for Respiratory Infection PCT/ US2013/023185, WO2013112865 A1. Has a licensing agreement: GeneOne Life Sciences. J. Constantinidis: Has received fees for lectures and participation on expert board meetings from GSK. E. De Corso: Lecture fees and/or participations at expert board meetings of Sanofi, GSK, Novartis, Astrazeneca. M. Desrosiers: has received clinical trial funding from AstraZeneca, GSK, Probio-nase Therapies and Sanofi, has participated in advisory boards for Regeneron Pharmaceuticals, Inc., Sanofi, and holds equity in Probionase Therapies. Z. Diamant: In the past 3 years: acted as consultant for Antabio and QPS-NL and received speaker fees or served on advisory boards for: ALK, Boehringer Ingel-heim, GlaxoSmithKline and Sanofi-Genzyme-Regeneron. R.G.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - Chronic rhinosinusitis (CRS) is known to affect around 5 % of the total population, with major impact on the quality of life of those severely affected (1). Despite a substantial burden on individuals, society and health economies, CRS often remains underdiagnosed, under-estimated and under-treated (2). International guidelines like the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) (3) and the International Consensus statement on Allergy and Rhinology: Rhinosinusitis 2021 (ICAR) (4) offer physicians insight into the recommended treatment options for CRS, with an overview of effective strategies and guidance of diagnosis and care throughout the disease journey of CRS.
AB - Chronic rhinosinusitis (CRS) is known to affect around 5 % of the total population, with major impact on the quality of life of those severely affected (1). Despite a substantial burden on individuals, society and health economies, CRS often remains underdiagnosed, under-estimated and under-treated (2). International guidelines like the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) (3) and the International Consensus statement on Allergy and Rhinology: Rhinosinusitis 2021 (ICAR) (4) offer physicians insight into the recommended treatment options for CRS, with an overview of effective strategies and guidance of diagnosis and care throughout the disease journey of CRS.
UR - http://www.scopus.com/inward/record.url?scp=85147143801&partnerID=8YFLogxK
U2 - https://doi.org/10.4193/Rhin22.344
DO - https://doi.org/10.4193/Rhin22.344
M3 - Article
C2 - 36507741
SN - 0300-0729
VL - 61
SP - 85
EP - 89
JO - Rhinology
JF - Rhinology
IS - 1
ER -